- Research article
- Open Access
- Open Peer Review
Cancer resistance of SR/CR mice in the genetic knockout backgrounds of leukocyte effector mechanisms: determinations for functional requirements
© Sanders et al; licensee BioMed Central Ltd. 2010
- Received: 20 November 2009
- Accepted: 31 March 2010
- Published: 31 March 2010
Spontaneous Regression/Complete Resistant (SR/CR) mice are a colony of cancer-resistant mice that can detect and rapidly destroy malignant cells with innate cellular immunity, predominately mediated by granulocytes. Our previous studies suggest that several effector mechanisms, such as perforin, granzymes, or complements, may be involved in the killing of cancer cells. However, none of these effector mechanisms is known as critical for granulocytes. Additionally, it is unclear which effector mechanisms are required for the cancer killing activity of specific leukocyte populations and the survival of SR/CR mice against the challenges of lethal cancer cells. We hypothesized that if any of these effector mechanisms was required for the resistance to cancer cells, its functional knockout in SR/CR mice should render them sensitive to cancer challenges. This was tested by cross breeding SR/CR mice into the individual genetic knockout backgrounds of perforin (Prf-/-), superoxide (Cybb-/), or inducible nitric oxide (Nos2-/).
SR/CR mice were bred into individual Prf-/-, Cybb-/-, or Nos2-/- genetic backgrounds and then challenged with sarcoma 180 (S180). Their overall survival was compared to controls. The cancer killing efficiency of purified populations of macrophages and neutrophils from these immunodeficient mice was also examined.
When these genetically engineered mice were challenged with cancer cells, the knockout backgrounds of Prf-/-, Cybb-/-, or Nos2-/- did not completely abolish the SR/CR cancer resistant phenotype. However, the Nos2-/- background did appear to weaken the resistance. Incidentally, it was also observed that the male mice in these immunocompromised backgrounds tended to be less cancer-resistant than SR/CR controls.
Despite the previously known roles of perforin, superoxide or nitric oxide in the effector mechanisms of innate immune responses, these effector mechanisms were not required for cancer-resistance in SR/CR mice. The resistance was functional when any one of these effector mechanisms was completely absent, except some noticeably reduced penetrance, but not abolishment, of the phenotype in the male background in comparison to female background. These results also indicate that some other effector mechanism(s) of granulocytes may be involved in the killing of cancer cells in SR/CR mice.
- Nitric Oxide
- Maximum Tolerate Dose
- Effector Mechanism
- S180 Cell
- Immunologic Synapse
Spontaneous Regression/Complete Resistant (SR/CR) mice are a mouse model that is capable of resisting lethal challenges with a wide variety of cancers [1, 2]. The resistance resides primarily in innate leukocytes consisting of granulocytes, monocytes, and natural killer cells which migrate to the site of the tumor, recognize the cancer cells via tight contact, and then destroy the tumor cells mainly through cytolysis [1, 2]. The cytolysis of cancer cells in SR/CR mice was previously indicated to involve multiple effector mechanisms [1–3], a number of which are associated with innate immunity. Specifically, perforin and granzymes were detected in the peritoneal fluid and in a fraction of the rosettes following a challenge with S180, in addition to a decrease in S180 killing by SR/CR macrophages following the inhibition of reactive oxygen species .
Several unanswered questions remain pertaining to the roles that these various effector mechanisms play in the killing of cancer cells by SR/CR leukocytes. In particular, it is unknown what proportion of the perforin positive cells were natural killer (NK) cells or cytotoxic T lymphocytes (CTL) and therefore the significance of perforin in the primary response and its role in the NK killing activity in these mice remain unclear. Furthermore, since inhibitors can have nonspecific effects on other enzymes or can have incomplete inhibition, it is not completely clear if the superoxide and nitric oxide effector mechanisms are required for the SR/CR cancer resistance phenotype, or for the cancer killing activity of an individual leukocyte population. In order to thoroughly evaluate these effector mechanisms during the primary anticancer response in a system with complete and specific inhibition, SR/CR mice were bred into genetic backgrounds deficient in perforin, superoxide, and nitric oxide.
Perforin is a protein found in secretory vesicles of CTL and NK cells, encoded by its gene on chromosome 10 . When released at the immunologic synapse between a leukocyte and its target, perforin polymerizes and forms pores in the target's membranes . While perforin is an inefficient cytolytic agent by itself; it facilitates the release of granzymes into the cytosol of the target cells and then triggers apoptotic pathways . In the perforin knockout mice (Prf-/-), CTL and NK cells are present in normal numbers, but are unable to lyse virus-infected or allogeneic fibroblasts in vitro . Perforin knockout mice are also more susceptible to viral pathogens, spontaneous B cell lymphomas, and transplanted or inducible tumors [7–11]. In the primary SR/CR response to cancer, it is likely that the absence of perforin would have the greatest effect on NK cells, since CTL's would require an initial priming event.
Superoxide is one type of reactive oxygen species that is produced by both macrophages and neutrophils for host defense. At the immunologic synapse or phagosome, superoxide is generated by NADPH oxidase. NADPH oxidase is a multi-subunit complex that catalyzes the reduction of molecular oxygen at the expense of NADPH . The gp91phox subunit, also known as NOX2, is an essential membrane bound protein that helps form the redox center of the enzyme [13–15]. If the gp91phox subunit is missing or defective, NADPH oxidase is inactive [16–18]. Mice with null alleles for gp91phox (Cybb-/-) on the X chromosome lack phagocyte superoxide production making them more susceptible to some bacterial and fungal infections . The absence of superoxide would likely affect both macrophages and neutrophils in the primary SR/CR response to cancer; and with twice the capacity for reactive oxygen species production, neutrophils may be affected the greatest .
Macrophages and neutrophils also produce nitric oxide, a reactive nitrogen species that is somewhat complementary to superoxide . At the immunologic synapse or phagosome, nitric oxide is generated by inducible nitric oxide synthase (Nos2) which converts arginine to citruline and nitric oxide, using molecular oxygen and NADPH [21, 22]. Mice with null Nos2 alleles on chromosome 11 (Nos2-/-) have virtually no serum nitric oxide response to lipopolysaccharide (LPS)  and have an altered response to many infections  and impaired wound healing . Since Nos2 inhibitors were previously shown not to have an effect on macrophage killing in vitro , it is likely that the absence of nitric oxide will only affect neutrophil killing activity during the primary SR/CR response to cancer in vivo.
Here, we report the findings of the SR/CR mice bred into the knockout backgrounds of Prf-/-, Cybb-/-, and Nos2-/- as it relates to the survival against a primary challenge with S180, and the evaluation of the cancer killing activity of individual leukocyte populations from these mice.
Cell Lines and Mouse Strains
The S180 cell line was obtained from the ATCC (Manassas, VA). S180 cells were either propagated in DMEM with 10% FBS at 37°C in 5% carbon dioxide or maintained by serial passages through wild-type (WT) C57BL/6 mice as cancerous ascites. WT C57BL/6J mice, C57BL/6-RAG1tm1Mom mice, B6.129S6-Cybbtm1Din/J, B6.129P2-Nos2tm1Lau/J, and C57BL/6-Prf1tm1Sdz/J mice were purchased from The Jackson Laboratory (Bar Harbor, ME). SR/CR mice in the C57BL/6 congenic background were bred at the ARP facility of WFU . Animals were housed under 12-hour light/dark cycles and received a standard laboratory chow diet. All protocols and procedures were approved by the IACUC of the WFU Health Sciences.
Prf Breeding and Screening
SR/CR C57BL/6 mice were bred with WT Prf-/- mice. At six weeks of age, the first filial generation (F1) progeny were screened with 1 × 10e6 S180 i.p., then 5 × 10e6 at ten weeks. Survivors were considered resistant, or F1 SR/CR Prf+/- mice, and used to breed the backcross (BC or F2) generation. F1 SR/CR Prf+/- were bred with WT Prf-/- mice. All of the BC progeny were Prf PCR genotyped at 3-4 weeks of age. At 6 weeks of age, the BC progeny were screened with 1 × 10e6 S180 i.p., then 5 × 10e6 at ten weeks. The second challenge of 5 × 10e6 was instituted as a safeguard against occasional failed first injections. All WT control mice were succumbed to the challenges via cancerous ascites. Healthy survivors were considered resistant, or BC SR/CR mice.
Tail snips were digested in DirectPCR Lysis Reagent-Tail (Viagen), with 0.4 mg/mL proteinase K. One uL of the lysate was used for each PCR reaction. Prf PCR genotyping was performed according to The Jackson Laboratory standard procedures by simultaneous amplification of the WT (Prf+) and knockout (Prf-) alleles using three primers: oIMR1100, 5'-GCTATCAGGACATAGCGTTGG-3'; oIMR3108, 5'-GGAGGCTCTGAGACAGGCTA-3'; and oIMR3109, 5'-TACCACCAAATGGGCCAAG-3'. The PCR yielded products of sizes 187 bp Prf+ and 250 bp Prf-, which were analyzed on 2% agarose gels.
Cybb Breeding and Screening
SR/CR C57BL/6 female mice were bred with WT CybbY/- male mice. At six weeks of age, the F1 progeny were screened with 1 × 10e6 S180 i.p., then 5 × 10e6 at ten weeks. Male survivors were designated F1 SR/CR CybbY/+. SR/CR female survivors were designated F1 SR/CR Cybb+/-, and used to breed the BC generation. F1 SR/CR female Cybb+/- were bred with WT CybbY/- male mice. All of the BC progeny were Cybb PCR genotyped at 3-4 weeks of age. At 6 weeks of age, the BC progeny were screened with 1 × 10e6 S180 i.p., then 5 × 10e6 at ten weeks. Survivors were considered resistant, or BC SR/CR mice.
Tail snips were digested in DirectPCR Lysis Reagent-Tail (Viagen), with 0.4 mg/mL proteinase K. 1 uL of the lysate was used for each PCR reaction. Cybb PCR genotyping was performed according to The Jackson Laboratory standard procedures by simultaneous amplification of the WT (Cybb+) and knockout (Cybb-) alleles using three primers: oIMR0517, 5'-AAGAGAAACTCCTCTGCTGTGAA-3'; oIMR0518, 5'-CGCACTGGAACCCCTGAGAAAGG-3'; and oIMR0519, 5'-GTTCTAATTCCATCAGAAGCTTATCG-3'. The PCR yielded products of sizes 240 bp Cybb+ and 195 bp Cybb-, which were analyzed on 2% agarose gels.
When showing signs of expected illness, the mice were sacrificed. Their tissues were fixed in 10% neutral buffered formalin, and subsequently embedded in paraffin. Sections were stained with hematoxylin and eosin and then examined.
Nos2 Breeding and Screening
SR/CR C57BL/6 mice were bred with WT Nos2-/- mice. At six weeks of age, the F1 progeny were screened with 1 × 10e6 S180 i.p., then 5 × 10e6 at ten weeks. Survivors were considered resistant, or F1 SR/CR Nos2+/- mice, and used to breed the BC generation. F1 SR/CR Nos2+/- were bred with WT Nos2-/- mice. All of the BC progeny were Nos2 PCR genotyped at 3-4 weeks of age. At six weeks of age, the BC progeny were screened with 1 × 10e6 S180 i.p., then 5 × 10e6 at ten weeks. Survivors were considered resistant, or BC SR/CR mice.
DNA was isolated from tail snips using the Wizard Genomic DNA Purification Kit (Promega, A1120). Nos2 PCR genotyping was performed according to The Jackson Laboratory standard procedures by simultaneous amplification of the WT (Nos2+) and knockout (Nos2-) alleles using three primers: oIMR1216, 5'-ACATGCAGAATGAGTACCGG-3'; oIMR1217, 5'-TCAACATCTCCTGGTGGAAC-3'; and oIMR1218, 5'-AATATGCGAAGTGGACCTCG-3'. The PCR yielded products of sizes 108 bp Nos2+ and 270 bp Nos2-, which were analyzed on 2% agarose gels.
Four days after a 2 mL i.p. injection with 2% thioglycolate (Sigma, B2551), macrophages were harvested by peritoneal lavage. The cells were cultured on tissue culture dishes for 1.5 hours in media (DMEM with 10% FBS) at 37°C. Non-adherent cells were removed by two rinses with phosphate buffered saline (PBS) containing calcium, and discarded. The adherent cells were incubated for 1 hour in 5 mM EDTA (in DMEM with 10% FBS) at 37°C. The macrophages were vigorously washed off using PBS without calcium, counted by Trypan Blue exclusion, and resuspended at the appropriate concentrations. Purity was > 95% macrophages as determined by hematoxylin staining and the unique morphology of macrophages.
Eighteen hours after a 2 mL i.p. injection of 2% thioglycolate, neutrophils were harvested by peritoneal lavage. The cells were cultured for 1 hour in media (DMEM with 10% FBS) at 37°C. Non-adherent cells were collected by several light rinses with PBS containing calcium, counted by Trypan Blue exclusion, and resuspended at the appropriate concentrations. Purity was > 85% neutrophils as determined by hematoxylin staining and typical polymorphic nuclei.
In a 96-well plate, 2 × 10e5 macrophages or 4 × 10e5 neutrophils were plated in DMEM with 10% FBS, at a final volume of 200 uL. Ten ug/mL stocks of interferon-gamma (IFNγ; Sigma, I4777) and lipopolysaccaride (LPS; E. Coli Serotype 0111:B4, Fluka, 62325) were freshly mixed in a 1:1 ratio. Four uL of the mixture was added to each stimulated well, while nothing was added to the unstimulated controls. The cells were incubated at 37°C for 24 hours. The following day, 50 uL of the media from each well was transferred to a flat-bottomed 96-well plate. In duplicate, a standard curve was also made with sodium nitrite in media (124-1.9 uM, and media alone; Sigma, S-2252) with a final volume of 50 uL per well. Fifty uL of Griess reagent (Fluka, 03553) was added to each well, and gently mixed. Large bubbles were popped with a heated needle. After 15 minutes at room temperature, the absorbance at 540 nm was read in a plate reader. The nitrite production for each sample was calculated (average stimulated - average unstimulated nitrite production), using the standard curve.
RAG1-/- recipients were given 8-10 × 10e6 macrophages or neutrophils i.p. The following day, the recipients were challenged with 1 × 10e4 S180 i.p. and their survival was monitored. Moribund mice were euthanized and examined for the presence of tumor. Mice that were healthy and ascites free, 6 weeks post injection, were considered resistant.
Statistical analysis was performed by the two-tailed Student's t-test. P-values less than 0.05 were regarded as statistically significant.
Prf Breeding and Screening
SR/CR F1 Prf+/- mice were crossed with WT Prf-/- mice. As expected, about half of the BC progeny born were Prf+/- and half were Prf-/- (Figure 1), indicating that perforin knockout was not embryonic lethal. When challenged with S180, 36% of the progeny survived, which was similar to the survival rate in the SR/CR F1 Prf+/- mice. However, there was a significant survival bias in the BC generation in which the females were twice as likely to be resistant than the males (p = 0.012). This was unexpected because there was no gender bias observed in the F1 generation, and neither the SR/CR mutation nor perforin have been associated with the sex chromosomes. In contrast, there was no significant difference in overall survival between the Prf+/- and Prf-/- mice, indicating that perforin was not required for the initial SR/CR phenotype in vivo.
Cybb Breeding and Screening
SR/CR F1 female Cybb+/- mice were crossed with WT male CybbY/- mice to generate the BC generation. The choice of using female F1s as breeders was to generate all 4 possible groups: SR/Cybb-KO/males, SR/Cybb-KO/females, WT/Cybb-KO/males and WT/Cybb-KO/females. As a result, SR/CR groups can be compared to WT groups that came from a same breeding scheme. There was an even distribution of mice born by gender and expected Cybb genotypes (Figure 2), indicating that there was no embryonic lethality. When challenged with S180, 26% of the progeny survived, which was similar to the survival rate seen in the F1 mice. There were no significant differences in survival by either gender or genotype; but there was a general trend that female Cybb+/- mice had a higher frequency of resistance than the other groups. Since there were resistant Cybb-/- females and CybbY/- males, superoxide did not appear to be required for the initial SR/CR phenotype in vivo.
Nos2 Breeding and Screening
SR/CR F1 Nos2+/- mice were crossed with WT Nos2-/- mice to generate the BC generation. As expected, about half the BC progeny were Nos2+/- and half were Nos2-/- (Figure 4), indicating that there was no embryonic lethality. When challenged with S180, 31% of the progeny survived, which was similar to the survival seen in the SR/CR F1 Nos2+/- mice. Again, there was a significant survival bias based on gender (p = 0.002), in which females were twice as likely to be resistant compared to males. Furthermore, there was a strong general trend that Nos2-/- mice were less resistant than Nos2+/- mice (p = 0.078). Importantly, this is the first time in which the absence of a single effector mechanism, namely Nos2, may have a negative effect, but not abolishment, on the germline transmission rate of SR/CR anticancer response in vivo.
Nitric Oxide Production
The SR/CR anticancer response was previously shown to involve multiple leukocyte subsets that can work collectively or independently [1–3]. It has also been shown that the anticancer response of the SR/CR mice involves multiple effector mechanisms . However, it was not known if the complete abolishment of any one effector mechanism would affect the SR/CR anticancer response due to the overlapping functional roles that many of the leukocyte populations displayed. Our current study shows that the SR/CR mice were capable of surviving a primary challenge with a lethal dose of S180 even with the genetic knockout of perforin, superoxide, or nitric oxide. In the absence of any one of these effector mechanisms, the cancer cells can still be destroyed leading to survival of the challenged mice. From these results, it is likely that only global immunosuppression, affecting multiple leukocyte populations and their effector mechanisms, would be able to abolish the SR/CR phenotype.
One intriguing finding was the important role that nitric oxide plays in the anticancer activity of the SR/CR macrophages and neutrophils. When SR/CR Nos2-/- macrophages and neutrophils were transferred into cancer-sensitive WT mice, the SR/CR Nos2-/- cells proved to be less protective against an S180 challenge compared to cells from SR/CR Nos2+/+ mice. These results suggest that nitric oxide may be one of the major effector mechanisms used by SR/CR macrophages and neutrophils to kill cancer cells. However, at the same time these results also suggest that the SR/CR macrophages and neutrophils have additional anticancer effector mechanisms in place, since the Nos2-/- transferred cells still provided some protection. In order to continue to evaluate the significance of other effector mechanisms, the killing activity of macrophages and neutrophils from SR/CR Nos2-/- mice will need to be assessed in combination with inhibitors of the other known effector mechanisms. Since the knockouts of perforin, superoxide and nitric oxide alone did not abolish the anticancer ability of the SR/CR mice, then the production of SR/CR mice with multiple effector mechanism knockouts may also be necessary for more complete characterization of the SR/CR phenotype.
The gender bias that was observed among all three knockout lines of mice was quite an unexpected finding. In several generations, female mice displayed a significantly higher percentage of cancer resistance among the challenged mice. Since the SR/CR mutation, Nos2 gene, and perforin gene are not X-linked, it is possible that there may be an unidentified X-linked gene that may enhance the SR/CR phenotype. However, since the gender bias is not consistently observed in the SR/CR breeding (data not shown), the bias may alternatively stem from the knockout backgrounds. The influence that hormone levels play may be another explanation for the differences observed between males and females. Many leukocyte subsets express hormone receptors  and in comparison to males, females tend to have more vigorous cellular and humoral immune reactions which are thought to make them more resistant to certain infections and at greater risk for autoimmunity . WT males and females appear equally sensitive to S180; however, when the SR/CR phenotype is in an immunocompromised background, the more vigorous immune response of the females may provide a slight survival advantage. One more explanation for the sex bias could reside in the fact that S180 immunostain positively for a Y-marker antigen (unpublished results), which would make S180 more antigenic in a female background. In males, this would be recognized as a self epitope, while in females it would be recognized as a foreign epitope and, therefore, could promote rejection of the transplanted cancer. The presence of a Y-antigen on S180 does not appear to matter for mice with a cancer-sensitive WT background, since males and females equally succumb to cancer challenge. However, when the SR/CR phenotype is introduced into an immunocompromised background, the extra antigenicity from the Y-antigen could provide a slight survival advantage for female mice.
Another possibility for this sex bias could be due to a possible weakening of the resistance strength as a result of continuous breeding for years. For example, in the first few generations of SR/CR mice, they could tolerate challenges of up to 10e9 S180 cells. In recent years, however, the maximum tolerated dose (MTD) seemed to have dropped to about 10e8 S180 cells (Cui et all, unpublished observations). Even with such a drop in MTD, the resistant phenotype of SR/CR mice is still unequivocal in comparison to non-resistant (WT) mice that would succumb to less than 10e5 or even less than 10e4 S180 cells. The decrease of MTD may reflect a possibility that the genetic components in the early generations may have multiple copies that were reduced to fewer copies or single copy in the later generations after years of breeding. If this is the case, the high MTD in early generations of SR/CR mice might have overcome some subtle influences, such as sex background. On the other hand, some subtle influences may show up when MTD was decreased as a result of fewer copy number for the underlying gene/mutation. The MTD could also be further decreased, but not abolished, by knockout of some participating but essential pathway for effector mechanisms. This could further exacerbate the impact of otherwise subtle influences.
Collectively these findings support the prior reports that the SR/CR anticancer response is the result of a concerted effort from several leukocyte populations that utilize multiple effector mechanisms. The many overlapping processes enable the host to achieve the same end result, elimination the cancer cells and survival. These findings also demonstrate that a highly effective anticancer response can be mediated by innate cellular immunity that requires no additional manipulation, supporting the idea that leukocytes of innate immunity could potentially be used as therapeutic agents to prevent or even to treat cancers.
The described studies were supported by grants from the Cancer Research Institute, the National Cancer Institute, and the Charlotte Geyer Foundation (to ZC).
- Cui Z, Willingham MC, Hicks AM, Alexander-Miller MA, Howard TD, Hawkins GA, Miller MS, Weir HM, Du W, DeLong CJ: Spontaneous regression of advanced cancer: identification of a unique genetically determined, age-dependent trait in mice. Proc Natl Acad Sci USA. 2003, 100: 6682-6687. 10.1073/pnas.1031601100.View ArticlePubMedPubMed CentralGoogle Scholar
- Hicks AM, Riedlinger G, Willingham MC, Alexander-Miller MA, Von Kap-Herr C, Pettenati MJ, Sanders AM, Weir HM, Du W, Kim J, et al: Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proc Natl Acad Sci USA. 2006, 103: 7753-7758. 10.1073/pnas.0602382103.View ArticlePubMedPubMed CentralGoogle Scholar
- Hicks AM, Willingham MC, Du W, Pang CS, Old LJ, Cui Z: Effector mechanisms of the anti-cancer immune responses of macrophages in SR/CR mice. Cancer Immun. 2006, 6: 11-PubMedGoogle Scholar
- Trapani JA, Kwon BS, Kozak CA, Chintamaneni C, Young JD, Dupont B: Genomic organization of the mouse pore-forming protein (perforin) gene and localization to chromosome 10. Similarities to and differences from C9. J Exp Med. 1990, 171: 545-557. 10.1084/jem.171.2.545.View ArticlePubMedGoogle Scholar
- Masson D, Tschopp J: Isolation of a lytic, pore-forming protein (perforin) from cytolytic T-lymphocytes. J Biol Chem. 1985, 260: 9069-9072.PubMedGoogle Scholar
- Trapani JA, Smyth MJ: Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol. 2002, 2: 735-747. 10.1038/nri911.View ArticlePubMedGoogle Scholar
- Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen KJ, Podack ER, Zinkernagel RM, Hengartner H: Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature. 1994, 369: 31-37. 10.1038/369031a0.View ArticlePubMedGoogle Scholar
- Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA: Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med. 2000, 192: 755-760. 10.1084/jem.192.5.755.View ArticlePubMedPubMed CentralGoogle Scholar
- Broek van den ME, Kagi D, Ossendorp F, Toes R, Vamvakas S, Lutz WK, Melief CJ, Zinkernagel RM, Hengartner H: Decreased tumor surveillance in perforin-deficient mice. J Exp Med. 1996, 184: 1781-1790. 10.1084/jem.184.5.1781.View ArticlePubMedGoogle Scholar
- Broek van den MF, Kagi D, Zinkernagel RM, Hengartner H: Perforin dependence of natural killer cell-mediated tumor control in vivo. Eur J Immunol. 1995, 25: 3514-3516. 10.1002/eji.1830251246.View ArticlePubMedGoogle Scholar
- Walsh CM, Matloubian M, Liu CC, Ueda R, Kurahara CG, Christensen JL, Huang MT, Young JD, Ahmed R, Clark WR: Immune function in mice lacking the perforin gene. Proc Natl Acad Sci USA. 1994, 91: 10854-10858. 10.1073/pnas.91.23.10854.View ArticlePubMedPubMed CentralGoogle Scholar
- Dinauer MC, Orkin SH: Chronic granulomatous disease. Annu Rev Med. 1992, 43: 117-124. 10.1146/annurev.me.43.020192.001001.View ArticlePubMedGoogle Scholar
- Dinauer MC: The respiratory burst oxidase and the molecular genetics of chronic granulomatous disease. Crit Rev Clin Lab Sci. 1993, 30: 329-369. 10.3109/10408369309082591.View ArticlePubMedGoogle Scholar
- Rotrosen D, Yeung CL, Leto TL, Malech HL, Kwong CH: Cytochrome b558: the flavin-binding component of the phagocyte NADPH oxidase. Science. 1992, 256: 1459-1462. 10.1126/science.1318579.View ArticlePubMedGoogle Scholar
- Segal AW, West I, Wientjes F, Nugent JH, Chavan AJ, Haley B, Garcia RC, Rosen H, Scrace G: Cytochrome b-245 is a flavocytochrome containing FAD and the NADPH-binding site of the microbicidal oxidase of phagocytes. Biochem J. 1992, 284 (Pt 3): 781-788.View ArticlePubMedPubMed CentralGoogle Scholar
- Pollock JD, Williams DA, Gifford MA, Li LL, Du X, Fisherman J, Orkin SH, Doerschuk CM, Dinauer MC: Mouse model of X-linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production. Nat Genet. 1995, 9: 202-209. 10.1038/ng0295-202.View ArticlePubMedGoogle Scholar
- Rae J, Newburger PE, Dinauer MC, Noack D, Hopkins PJ, Kuruto R, Curnutte JT: X-Linked chronic granulomatous disease: mutations in the CYBB gene encoding the gp91-phox component of respiratory-burst oxidase. Am J Hum Genet. 1998, 62: 1320-1331. 10.1086/301874.View ArticlePubMedPubMed CentralGoogle Scholar
- Yu L, Cross AR, Zhen L, Dinauer MC: Functional analysis of NADPH oxidase in granulocytic cells expressing a delta488-497 gp91(phox) deletion mutant. Blood. 1999, 94: 2497-2504.PubMedGoogle Scholar
- Nathan C, Shiloh MU: Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc Natl Acad Sci USA. 2000, 97: 8841-8848. 10.1073/pnas.97.16.8841.View ArticlePubMedPubMed CentralGoogle Scholar
- Shiloh MU, MacMicking JD, Nicholson S, Brause JE, Potter S, Marino M, Fang F, Dinauer M, Nathan C: Phenotype of mice and macrophages deficient in both phagocyte oxidase and inducible nitric oxide synthase. Immunity. 1999, 10: 29-38. 10.1016/S1074-7613(00)80004-7.View ArticlePubMedGoogle Scholar
- Marletta MA: Nitric oxide synthase structure and mechanism. J Biol Chem. 1993, 268: 12231-12234.PubMedGoogle Scholar
- Nathan C, Xie QW: Regulation of biosynthesis of nitric oxide. J Biol Chem. 1994, 269: 13725-13728.PubMedGoogle Scholar
- Laubach VE, Shesely EG, Smithies O, Sherman PA: Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc Natl Acad Sci USA. 1995, 92: 10688-10692. 10.1073/pnas.92.23.10688.View ArticlePubMedPubMed CentralGoogle Scholar
- Nathan C: Inducible nitric oxide synthase: what difference does it make?. J Clin Invest. 1997, 100: 2417-2423. 10.1172/JCI119782.View ArticlePubMedPubMed CentralGoogle Scholar
- Yamasaki K, Edington HD, McClosky C, Tzeng E, Lizonova A, Kovesdi I, Steed DL, Billiar TR: Reversal of impaired wound repair in iNOS-deficient mice by topical adenoviral-mediated iNOS gene transfer. J Clin Invest. 1998, 101: 967-971. 10.1172/JCI2067.View ArticlePubMedPubMed CentralGoogle Scholar
- Weller PF, Goetzl EJ, Austen KF: Identification of human eosinophil lysophospholipase as the constituent of Charcot-Leyden crystals. Proc Natl Acad Sci USA. 1980, 77: 7440-7443. 10.1073/pnas.77.12.7440.View ArticlePubMedPubMed CentralGoogle Scholar
- Harbord M, Novelli M, Canas B, Power D, Davis C, Godovac-Zimmermann J, Roes J, Segal AW: Ym1 is a neutrophil granule protein that crystallizes in p47phox-deficient mice. J Biol Chem. 2002, 277: 5468-5475. 10.1074/jbc.M110635200.View ArticlePubMedGoogle Scholar
- Nio J, Fujimoto W, Konno A, Kon Y, Owhashi M, Iwanaga T: Cellular expression of murine Ym1 and Ym2, chitinase family proteins, as revealed by in situ hybridization and immunohistochemistry. Histochem Cell Biol. 2004, 121: 473-482. 10.1007/s00418-004-0654-4.View ArticlePubMedGoogle Scholar
- Bouman A, Heineman MJ, Faas MM: Sex hormones and the immune response in humans. Hum Reprod Update. 2005, 11: 411-423. 10.1093/humupd/dmi008.View ArticlePubMedGoogle Scholar
- Ansar Ahmed S, Penhale WJ, Talal N: Sex hormones, immune responses, and autoimmune diseases. Mechanisms of sex hormone action. Am J Pathol. 1985, 121: 531-551.PubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/10/121/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.